Advancements in the Treatment of Desmoid Tumors - Episode 11

DeFi: Nirogacestat in Patients with Progressing Desmoid Tumors

February 12, 2024

Jonathan C. Trent, MD, PhD, Mark Agulnik, MD, Marilyn Bui, MD, PhD, Chandrajit Raut, MD

Jonathan Trent, MD, PhD, discusses the rationale and design of the DeFi study, instrumental in the FDA approval of nirogacestat, and explores key efficacy and safety findings from this research.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: An Overview of the Landscape Surrounding Desmoid Tumors

EP. 2: Expert Perspectives on the Pathogenesis and Diagnosis of Desmoid Tumors

EP. 3: Signs and Symptoms of Desmoid Tumors and Their Impact on Quality of Life

EP. 4: Active Surveillance in Frontline Management of Desmoid Tumors

EP. 5: The Evolving Role of Surgery in the Management of Desmoid Tumors

EP. 6: Treatment Strategies Using Radiotherapy or Other Locoregional Approaches in Desmoid Tumors

EP. 7: Approaches to Systemic Therapy in Desmoid Tumors: The Role of Chemotherapy

EP. 8: The Role of Supportive Care Measures in Patients with Desmoid Tumors

EP. 9: Desmoid Tumors in Women: Special Considerations for Pregnancy and Contraception

EP. 10: Targeting NOTCH Pathway Signaling with Nirogacestat

Now Viewing

EP. 11: DeFi: Nirogacestat in Patients with Progressing Desmoid Tumors

EP. 12: Impact of Nirogacestat on Pain, Quality of Life, and Fertility in Patients with Desmoid Tumors

EP. 13: Nirogacestat's Impact on the Future Treatment of Desmoid Tumors

EP. 14: Future Perspectives on the Treatment of Desmoid Tumors